Anti-CBL Polyclonal Antibody for WB, IHC-P, IF/ICC, IP, ELISA - P22681

Core Product Specifications and Parameters

Biological Background: CBL Function and Localization

• CBL (also known as c-Cbl, RNF55, CBL2) is an E3 ubiquitin-protein ligase and a proto-oncogene that functions as a negative regulator of multiple signaling pathways by mediating ubiquitination of cell surface receptors, leading to their proteasomal degradation. Related references: PMID:10514377 PMID:11896602 PMID:14661060
• Recognizes and ubiquitinates activated receptor tyrosine kinases (RTKs) such as KIT, FLT1, FGFR1/2, PDGFRA/B, CSF1R, EPHA8, and KDR to terminate their signaling. Related references: PMID:15190072 PMID:18374639 PMID:21596750
• Targets other signaling proteins including EGFR, SPRY2, and SRC family kinases for ubiquitination and degradation. Related references: PMID:17094949 PMID:17974561
• Mediates LAG3-dependent inhibition of TCR signaling by catalyzing 'Lys-63'-linked ubiquitination of LAG3, which unleashes its C-terminus from the membrane to initiate inhibitory signals. Related references: PMID:40101708
• Plays a critical role in osteoclast function and bone resorption, and regulates osteoblast differentiation and apoptosis; phosphorylation at Tyr-731 recruits PI3K to the membrane to drive osteoclast signaling. Related references: PMID:14739300 PMID:15190072 PMID:18374639
• Localizes to the cytoplasm, cell membrane, cell projections (cilium), and Golgi apparatus, consistent with its roles in receptor trafficking and signaling.
• Contains a RING finger domain (zinc-finger), phosphotyrosine-binding region, and proline-rich repeats, and is regulated by phosphorylation.

Experimental Guidance and Technical Tips

• The immunogen corresponds to the C-terminal region (aa 850-906) of human CBL. For Western blot, expect a band at ~100 kDa; post-translational modifications may cause slight shifts.
• For immunohistochemistry (IHC-P), optimize antigen retrieval and antibody dilution experimentally; the antibody detects both membrane and cytoplasmic CBL.
• In immunoprecipitation, the polyclonal nature may offer robust pull-down efficiency; validate in the appropriate cell or tissue lysate.
• For IF/ICC, fixation and permeabilization conditions should be titrated to preserve both membrane and intracellular pools of CBL.
• Cross-reactivity with mouse and rat is reported; detection in other species may be possible but should be verified by sequence homology.
• As with any polyclonal antibody, lot-to-lot variability is possible; we recommend including appropriate controls and validating in the relevant sample system.

CamelBio: Your One-Stop Sourcing Bridge

CamelBio provides comprehensive IVD raw material solutions, from validated antibody pairs and bulk reagents to rare target sourcing, supporting your research and diagnostic development needs. This anti-CBL polyclonal antibody is ideal for studying ubiquitin-mediated signaling, receptor trafficking, and osteoclast biology. Contact us for custom antibody development, technical consulting, and seamless integration into your IVD workflows.